HPV vaccine could drastically reduce cervical and other cancers globally

Cervical cancer affects more than half a million women and causes more than a quarter of a million deaths each year globally. Almost all cervical cancers result from a human papillomavirus, or HPV, infection. HPV infections cause cancers in other parts of the body, too. But the latest HPV vaccine could prevent most infections -- and millions of cancers -- worldwide, according to an article by Cosette Wheeler, PhD, and her collaborators.

The article describing the HPV vaccine and strategies to overcome issues with its use was published online by the American Society of Clinical Oncology. ASCO shared a print of the article with the 30,000 attendees at its Annual Meeting this year. Annual Meeting attendees included top oncologists from around the country and the world. Wheeler is an international HPV expert, a University of New Mexico Regents Professor and a member of The University of New Mexico Comprehensive Cancer Center. She and the other authors of the article served as expert panel members for the Primary Prevention of Cervical Cancer: ASCO Resource-Stratified Guideline.

The HPV vaccine can prevent HPV infection if the vaccine is given before exposure to any of the HPV types that the vaccine protects against. Different formulas of the HPV vaccine protect against different types of HPV. Only two types, HPV16 and HPV18, cause 70 percent or more of all invasive cervical cancers and all HPV vaccine formulas protect against these two. The nonavalent formula of the HPV vaccine is the most protective: it protects against HPV16, HPV18 and five other cancer-causing HPV types. As of June, 2017, only the nonavalent HPV vaccine is available in the United States.

Currently, though, global HPV vaccination rates are low. The vaccine must be given in two or three doses. This can prove difficult for teens and preteens who lack easy and affordable access to a clinic and who do not receive regular medical check-ups. The article suggests giving the HPV vaccine with other childhood vaccines as a critical strategy to lessen this burden. The article also cites studies that have shown two doses to be as protective as three doses if vaccination is started at a younger age. The United States Advisory Committee on Immunization Practices now recommends two doses of HPV vaccine for both boys and girls, but only if they receive their first HPV vaccine dose between ages 9 and 14. After a teen s fifteenth birthday, the Committee still recommends three HPV vaccine doses.

Find more information at:

Materials provided by . Note: Content may be edited for style and length.

University of New Mexico Comprehensive Cancer Center. "HPV vaccine could drastically reduce cervical and other cancers globally." ScienceDaily. ScienceDaily, 12 June 2017. .

University of New Mexico Comprehensive Cancer Center. "HPV vaccine could drastically reduce cervical and other cancers globally." ScienceDaily. (accessed June 12, 2017).
News Topics :
In one of the first large studies to explore the possible impact of HPV vaccination on oral HPV infections, researchers found it may confer a high degree of protection. The...
The American Society of Clinical Oncology ASCO has issued a clinical practice guideline on human papillomavirus HPV vaccination for the prevention of cervical cancer. This is the first guideline on...
Cancer is most curable when it s detected at its earliest stages. While it is much too soon to identify the specific cause of this positive trend, or determine whether...
The number of cancers associated with the human papillomavirus HPV is on the rise in the United States, reaching nearly 39, 000 each year, a government report said Thursday. The case...
Pap smears that detect changes in cervical cells are one of three cancer screening methods suggested by the World Health Organization. Craig Lassig/AP Images for College of American Pathologists Girls...